Visão geral da empresa
Ascentage Pharma Group International operates as a clinical-stage biotechnology entity dedicated to developing novel therapies for cancers, chronic hepatitis B virus infections, and age-related diseases primarily within the Mainland China market. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, positioning itself to capitalize on high-value pharmaceutical innovations and unmet medical needs in specialized therapeutic areas. Currently, the entity maintains a market capitalization of $2.54B and employs 767 professionals to support its extensive research and development pipeline. With a trailing twelve-month revenue of $574.12M, the company demonstrates a significant operational footprint that reflects its established position as a substantial player in the biotechnology landscape, despite being in a clinical-stage development phase.
Saúde financeira
The company reported a trailing twelve-month revenue of $574.12M, yet this figure is contrasted by a net income of $-1,242,769,024 and an EBITDA of $-1,132,252,032, revealing a substantial gap between top-line growth and profitability driven by high operating expenses inherent to clinical-stage development. Although free cash flow data is not available in the current reporting period, the presence of $2.47B in cash reserves suggests a robust liquidity position that could support ongoing R&D expenditures and potential strategic acquisitions. The gross margin stands at an impressive 91.5%, indicating strong pricing power and low cost of goods sold relative to sales, while the operating margin of -193.3% and profit margin of -216.5% highlight the intense cash burn required to advance clinical trials before commercialization. The balance sheet shows a debt load of $1.98B against cash holdings of $2.47B, resulting in a debt-to-equity ratio of 148.38, which characterizes a leveraged capital structure common for biotechnology firms investing heavily in future growth. Short-term liquidity is supported by a current ratio of 1.79, suggesting the company possesses sufficient current assets to cover its short-term liabilities without immediate distress. Return on equity is recorded at -154.6% and return on assets at -23.0%, metrics that reflect the current inability to generate shareholder value from existing assets due to significant accumulated losses rather than operational inefficiency.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E ratio is -22.23, implying that future earnings estimates are also negative and that traditional earnings-based valuation models are currently inapplicable. The price-to-book ratio is elevated at 51.26, indicating that the market values the company's equity at a significant premium over its accounting book value, likely reflecting high expectations for the success of its pipeline assets. Alternative valuation metrics such as the price-to-sales ratio of 4.43 and an EV/EBITDA of -8.27 provide context for investors assessing the company based on revenue generation and enterprise value relative to earnings potential, rather than profitability. The stock has exhibited significant volatility, trading between a 52-week high of $48.45 and a 52-week low of $17.55, representing a trading range of approximately 63.8% between these extremes. The beta value of 0.81 indicates that the stock's price volatility is slightly lower than the broader market, suggesting a moderate correlation with general market movements despite the inherent risks of the biotechnology sector.
Growth & Income
Revenue growth year-over-year has accelerated to 117.0%, driven by expanding sales or new product launches, whereas earnings growth is N/A due to continued negative net income, highlighting a phase where revenue expansion precedes profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, which aligns with a strategy of reinvesting all available capital into research and development to advance its clinical-stage therapies. The absence of dividend payments underscores the capital-intensive nature of the business model, where preserving cash for operational needs and pipeline progression is prioritized over income distribution to investors. Overall, the company presents a high-growth, non-income profile typical of early-to-mid-stage biotechnology firms that rely on market valuation appreciation rather than current earnings or dividends to attract capital.